NDA 020533 · Fresenius Kabi USA
Naropin
Ropivacaine Hydrochloride · Injection
NovelLast checked: Nov 19, 2026Latest source record: Jun 28, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Sep 24, 1996
Approved uses
2
Original approval plus efficacy supplements
Registered trials
1,293
162 Phase 3, 97 recruiting
FAERS reports
2,453
2,216 serious, 127 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 22, 2026.
NAROPIN is indicated for the production of local or regional anesthesia for surgery and for acute pain management. Surgical Anesthesia : epidural block for surgery including cesarean section; major nerve block; local infiltration Acute Pain Management : epidural continuous infusion or intermittent bolus, e.g., postoperative or labor; local infiltration NAROPIN is an amide local anesthetic indicated in adults for the production of local or regional anesthesia for surgery and for acute pain management. (1) Surgical Anesthesia : epidural block for surgery including cesarean section; major nerve block; local infiltration Acute Pain Management : epidural continuous infusion or intermittent bolus, e.g., postoperative or labor; local infiltration
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 2, 2000 Supplement 2 · Efficacy Review
- Sep 24, 1996 Original approval · Type 1 - New Molecular Entity Review
13 products under this application
- NAROPIN · ROPIVACAINE HYDROCHLORIDE 150MG/30ML (5MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
- NAROPIN · ROPIVACAINE HYDROCHLORIDE 200MG/100ML (2MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
- NAROPIN · ROPIVACAINE HYDROCHLORIDE 75MG/10ML (7.5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INJECTION · Discontinued
- NAROPIN · ROPIVACAINE HYDROCHLORIDE 150MG/20ML (7.5MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
- NAROPIN · ROPIVACAINE HYDROCHLORIDE 1GM/200ML (5MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
- NAROPIN · ROPIVACAINE HYDROCHLORIDE 40MG/20ML (2MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
- NAROPIN · ROPIVACAINE HYDROCHLORIDE 500MG/100ML (5MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
- NAROPIN · ROPIVACAINE HYDROCHLORIDE 400MG/200ML (2MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
- NAROPIN · ROPIVACAINE HYDROCHLORIDE 50MG/10ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INJECTION · Discontinued
- NAROPIN · ROPIVACAINE HYDROCHLORIDE 100MG/10ML (10MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
- NAROPIN · ROPIVACAINE HYDROCHLORIDE 200MG/20ML (10MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
- NAROPIN · ROPIVACAINE HYDROCHLORIDE 100MG/20ML (5MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
- NAROPIN · ROPIVACAINE HYDROCHLORIDE 20MG/10ML (2MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Ropivacaine" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)Pivotal-lookingRecruiting
Second Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT06452147 · 1,860 participants (planned) · Start Jun 19, 2024 · Primary completion Jul 30, 2028
Drug: Bupivacaine liposome; Regular local anesthetic and 1 more · For: Anesthesia; Hip Fractures; Dementia and 2 more
Sites: Dongyang, China; Hangzhou, China; Jinhua, China · 13 sites in all
First Affiliated Hospital of Harbin Medical UniversityAcademic, hospital or other
NCT06068166 · 1,840 participants · Start Jul 1, 2013 · Primary completion Aug 31, 2019
Drug: GDMT · For: Heart Failure With Reduced Ejection Fraction; Thoracic Epidural Anesthesia
- Epidural Anesthesia-analgesia and Long-term OutcomePivotal-lookingCompleted
Peking University First HospitalAcademic, hospital or other
NCT03012945 · 1,802 participants · Start Nov 1, 2014 · Primary completion Sep 30, 2019
Drug: Combined epidural-general anesthesia; General anesthesia · For: Elderly; Malignant Tumor; Surgical Resection and 2 more
Sites: Beijing, China · 5 sites in all
- Comparison of Epidural Labor Analgesia With Dexmedetomidine or SufentanilPivotal-lookingStatus unknown
Fudan UniversityAcademic, hospital or other
NCT03622047 · 1,800 participants (planned) · Start Aug 15, 2018 · Primary completion Aug 1, 2020
Drug: Dexmedetomidine ropivacaine; No analgesia labor · For: Pharmacological Action
Sites: Shanghai, China
- Effect of Tramadol in Prevention of Postpartum DepressionPivotal-lookingCompleted
Xinqiao Hospital of ChongqingAcademic, hospital or other
NCT03309163 · 1,230 participants · Start Oct 9, 2017 · Primary completion Jun 13, 2019
Drug: Tramadol; Hydromorphone and 1 more · For: Caesarean Section
Sites: Chongqing, China
- Epidural Labor Analgesia and Infant NeurobehaviorPivotal-lookingCompleted
Nanjing Medical UniversityAcademic, hospital or other
NCT00987441 · 1,200 participants · Start Sep 2009 · Primary completion Jul 2011
Drug: Ropivacaine and sufentanil; Ropivacaine and sufentanil and 4 more · For: Labor Pain
Sites: Nanjing, China
- Combined Spinal-epidural Anesthesia for Cesarean Section Without Prophylactical Prehydration and VasopressorsPivotal-lookingStatus unknown
Shenzhen People's HospitalAcademic, hospital or other
NCT03497364 · 930 participants (planned) · Start May 1, 2018 · Primary completion Nov 30, 2021
Drug: bupivacaine; ropivacaine · For: Cesarean Section; Anesthesia, Spinal
Sites: Shenzhen, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- vomiting622
- dyspnoea618
- pneumonia612
- drug hypersensitivity607
- oedema599
- asthma576
- wheezing567
- pain268
- malaise242
- respiratory tract infection222
- chest pain200
- cough188
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 48 |
| 2005 | 56 |
| 2006 | 40 |
| 2007 | 47 |
| 2008 | 95 |
| 2009 | 81 |
| 2010 | 102 |
| 2011 | 139 |
| 2012 | 125 |
| 2013 | 30 |
| 2014 | 44 |
| 2015 | 66 |
| 2016 | 54 |
| 2017 | 34 |
| 2018 | 54 |
| 2019 | 78 |
| 2020 | 48 |
| 2021 | 51 |
| 2022 | 161 |
| 2023 | 221 |
| 2024 | 306 |
| 2025 | 342 |
| 2026 | 231 |
Recalls
1 FDA enforcement reports for this application.
Jul 16, 2026 · Class II · Ongoing
Presence of Particulate Matter: Hair was found in products
Shortages
FDA's drug shortage list.
Current · updated Nov 18, 2026
Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23).
Current · updated Nov 18, 2026
Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20). Delay in shipping of the drug
Current · updated Nov 18, 2026
Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21). Check wholesalers for inventory
Current · updated Nov 18, 2026
Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20). Demand increase for the drug
Current · updated Nov 18, 2026
Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11).
Current · updated Nov 18, 2026
Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Naropin* (Ropivacaine HCL/PF*) · HCPCS J2795
2024 spending
$48K
Beneficiaries
9,909
16,024 claims
Per beneficiary
$5
2024 ASP limit $0.07 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $28,823 |
| 2021 | $40,587 |
| 2022 | $48,870 |
| 2023 | $53,356 |
| 2024 | $48,141 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of ropivacaine combined with sufentanil epidural anesthesia in abdominal surgery.
Li S, Zhan Y, Bu S, et al. · Pak J Pharm Sci 2023 · Randomized Controlled Trial
- Analgesic Efficacy of Ropivacaine Infiltration on Early Post-Tonsillectomy Pain in Pediatrics.
Albazee E, Abdelwahab OA, Abdelaziz A, et al. · Laryngoscope 2024 · Systematic Review, Meta-Analysis
- Intrathecal anesthesia: ropivacaine versus bupivacaine.
Malinovsky JM, Charles F, Kick O, et al. · Anesth Analg 2000 · Clinical Trial, Comparative Study
- Effects of dexmedetomidine as an adjuvant to ropivacaine or ropivacaine alone on duration of postoperative analgesia: A systematic review and meta-analysis of randomized controlled trials.
Li F, Guo L, Huang Z, et al. · PLoS One 2023 · Meta-Analysis, Systematic Review
- Dose-response of epidural ropivacaine with 0.4ߕμgߕmL-1 of dexmedetomidine for labor analgesia: A prospective double-blinded study.
Yin J, Cao S, Lei J, et al. · Medicine (Baltimore) 2024 · Randomized Controlled Trial
- [Locally administered ropivacaine vs. standard analgesia for laparoscopic cholecystectomy].
Chavarría-Pérez T, Cabrera-Leal CF, Ramírez-Vargas S, et al. · Rev Med Inst Mex Seguro Soc 2015 · Comparative Study, Randomized Controlled Trial
Sponsor: Fresenius Kabi USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.